{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:48:49Z","timestamp":1793332129102,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bmc.2024.117605","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T21:05:47Z","timestamp":1705179947000},"page":"117605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Medicinal chemistry perspectives on the development of piperazine-containing HIV-1 inhibitors"],"prefix":"10.1016","volume":"99","author":[{"given":"Christiana","family":"Abimbola Salubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna S","family":"Abbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazeeen","family":"Jahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-5021","authenticated-orcid":false,"given":"Salam","family":"Titinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117605_b0005","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2014.09.054","article-title":"Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization","volume":"87","author":"Liu","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect Chemother."},{"key":"10.1016\/j.bmc.2024.117605_b0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/cbdd.13953","article-title":"Synthesis and antiviral activity of diverse heterocyclic scaffolds","volume":"100","author":"Sharma","year":"2022","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117605_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmc.2024.117605_b0030","doi-asserted-by":"crossref","first-page":"e0241071","DOI":"10.1371\/journal.pone.0241071","article-title":"HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey","volume":"15","author":"Moyo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117605_b0035","unstructured":"P\u00e9rez L, Machado LY, Pintos Y, D\u00edaz HM, Kour\u00ed V, Aragon\u00e9s C, Correa C, Alem\u00e1n, Y, Silva E, Blanco dAM, et al., Antiretroviral drug resistance transmitted in HIV-1 newly diagnosed cuban patients. April 2013-April 2014. Clin Res HIV\/AIDS. 2020;7(1):1050. DOI: 10.47739\/2374-0094\/1050."},{"key":"10.1016\/j.bmc.2024.117605_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2022.107675","article-title":"In silico design, synthesis and anti-HIV activity of quinoline derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"98","author":"Singh","year":"2022","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0045","doi-asserted-by":"crossref","unstructured":"McCluskey SM, Pepperrell T, Hill A, Venter WDF, Gupta RK, Siedner MJ. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021;35 (Suppl 2):S127-S135. DOI: 10.1097\/QAD.0000000000003082.","DOI":"10.1097\/QAD.0000000000003082"},{"key":"10.1016\/j.bmc.2024.117605_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?","volume":"53","author":"Mehellou","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmc.2024.117605_b0060","first-page":"1","article-title":"Molecular modeling of potential dual inhibitors of HIV reverse transcriptase and integrase","volume":"08","author":"Cabrera","year":"2018","journal-title":"Comput Mol Biol."},{"key":"10.1016\/j.bmc.2024.117605_b0065","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bmcl.2010.12.109","article-title":"Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate","volume":"21","author":"Nishizawa","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114471","article-title":"Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features","volume":"238","author":"Gao","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0075","first-page":"1","article-title":"Anti-HIV drug discovery, development and synthesis of delavirdine: review article","author":"Jemal","year":"2019","journal-title":"Int Res J Pure Appl Chem."},{"key":"10.1016\/j.bmc.2024.117605_b0080","first-page":"1955","article-title":"Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir","volume":"30","author":"Wang","year":"2021","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2024.117605_b0085","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/j.tetlet.2015.01.074","article-title":"An expedient synthesis of maraviroc (UK-427,857) via C-H functionalization","volume":"56","author":"Bedell","year":"2015","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0090","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117605_b0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117605_b0100","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1021\/acs.oprd.6b00163","article-title":"A robust kilo-scale synthesis of doravirine","volume":"20","author":"Campeau","year":"2016","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117605_b0105","article-title":"Process for synthesis of Etravirine","author":"Gurjar","year":"2018","journal-title":"EP2342186B1"},{"key":"10.1016\/j.bmc.2024.117605_b0110","unstructured":"Saeed A, Frank G, Vergheses J, Tyler M. Lowcost, high yield synthesis of nevirapine. WO2016118586A1, 2016."},{"key":"10.1016\/j.bmc.2024.117605_b0115","unstructured":"Gurjar MK, Maikap GS, Joshi SG, Badhe SA, Samit MS. An improved rilpivirine process. WO2012143937A2."},{"key":"10.1016\/j.bmc.2024.117605_b0120","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1021\/jo981170l","article-title":"Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor","volume":"63","author":"Pierce","year":"1998","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0125","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/acs.oprd.0c00155","article-title":"Seeking for selectivity and efficiency: new approaches in the synthesis of raltegravir","volume":"24","author":"Caputo","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117605_b0130","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/acs.oprd.1c00139","article-title":"Six-step gram-scale synthesis of the human immunodeficiency virus integrase inhibitor dolutegravir sodium","volume":"25","author":"Dietz","year":"2021","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117605_b0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1021\/acs.oprd.9b00031","article-title":"Review of synthetic routes and final forms of integrase inhibitors dolutegravir, cabotegravir, and bictegravir","volume":"23","author":"Hughes","year":"2019","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117605_b0140","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117605_b0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1021\/acs.molpharmaceut.9b00871","article-title":"Synthesis and characterization of long-acting darunavir prodrugs","volume":"17","author":"Banoub","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2024.117605_b0150","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1055\/s-2001-18434","article-title":"Syntheses of FDA approved HIV protease inhibitors","volume":"2001","author":"Ghosh","year":"2001","journal-title":"Synthesis (stuttg)."},{"key":"10.1016\/j.bmc.2024.117605_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/op7001563","article-title":"An efficient and practical synthesis of the HIV protease inhibitor atazanavir via a highly diastereoselective reduction approach","volume":"12","author":"Fan","year":"2008","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmc.2024.117605_b0160","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5, 6-dihydro-4-hydroxy-2-pyrone sulfonamide class","volume":"41","author":"Turner","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1741-7015-11-249","article-title":"What if HIV were unable to develop resistance against a new therapeutic agent?","volume":"11","author":"Wainberg","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.bmc.2024.117605_b0170","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nchem.1395","article-title":"Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro","volume":"4","author":"DeChristopher","year":"2012","journal-title":"Nat Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.bmc.2024.117605_b0180","doi-asserted-by":"crossref","unstructured":"Sharma S, Anand N. Chapter 5 - Piperazines. In: Pharmacochemistry Library, Sharma, S., Anand, N. (Eds); Vol. 25; Elsevier, 1997; pp 148-170. DOI: 1016\/S0165-7208(97)80027-X.","DOI":"10.1016\/S0165-7208(97)80027-X"},{"key":"10.1016\/j.bmc.2024.117605_b0185","doi-asserted-by":"crossref","first-page":"15213","DOI":"10.1039\/D1RA00341K","article-title":"Piperazine based antimicrobial polymers: a review","volume":"11","author":"Jalageri","year":"2021","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2024.117605_b0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/fcp.12408","article-title":"Piperazine derivatives with central pharmacological activity used as therapeutic tools","volume":"33","author":"Brito","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.bmc.2024.117605_b0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/dta.307","article-title":"Current awareness of piperazines: pharmacology and toxicology","volume":"3","author":"Elliott","year":"2011","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.bmc.2024.117605_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098280","article-title":"Design, synthesis, and anti-PVY biological activity of 1,3,5-triazine derivatives containing piperazine structure","volume":"24","author":"Bai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117605_b0205","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1055\/s-0036-1589491","article-title":"Recent advances in piperazine synthesis","volume":"49","author":"Gettys","year":"2017","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2024.117605_b0210","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ejmech.2016.09.007","article-title":"New isoxazolidinone and 3,4-dehydro-beta-proline derivatives as antibacterial agents and MAO-inhibitors: a complex balance between two activities","volume":"124","author":"Ferrazzano","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0215","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1021\/acschembio.8b00790","article-title":"Fluorescent benzothiazinone analogues efficiently and selectively label Dpre1 in mycobacteria and actinobacteria","volume":"13","author":"Sommer","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2024.117605_b0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmech.2013.04.025","article-title":"Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement","volume":"64","author":"Jiang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/acs.jmedchem.7b01138","article-title":"Alkylated piperazines and piperazine-azole hybrids as antifungal agents","volume":"61","author":"Thamban Chandrika","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0230","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejmech.2015.06.035","article-title":"Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth","volume":"101","author":"Chollet","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113330","article-title":"Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors","volume":"217","author":"Kayamba","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0240","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.bmcl.2009.03.020","article-title":"Synthesis and biological evaluation of novel 4-(hetero) aryl-2-piperazino quinazolines as anti-leishmanial and anti-proliferative agents","volume":"19","author":"Kumar","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0245","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1021\/jm301593r","article-title":"Garcinia xanthones as orally active antitumor agents","volume":"56","author":"Zhang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2015.10.053","article-title":"1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation","volume":"107","author":"Abou-Seri","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0255","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1021\/jm901184n","article-title":"Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0260","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.bmcl.2010.04.110","article-title":"Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists","volume":"20","author":"Lucas","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0265","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejmech.2013.04.007","article-title":"Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y(1)(2) receptor","volume":"65","author":"Bach","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0270","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","article-title":"8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3methyl-1-(4-methyl-quinazolin-2-ylmethyl)3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes","volume":"50","author":"Eckhardt","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0275","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/cmdc.202100045","article-title":"Piperazine, a key substructure for antidepressants: its role in developments and structure-activity relationships","volume":"16","author":"Kumar","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117605_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112967","article-title":"An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: a review","volume":"210","author":"Girase","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0285","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2015.07.026","article-title":"Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents","volume":"102","author":"Shaquiquzzaman","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0290","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00210-023-02413-9","article-title":"Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study","volume":"396","author":"Alsubi","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bmc.2024.117605_b0295","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1039\/C9RA09115G","article-title":"Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS\/MS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites","volume":"10","author":"Attwa","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2024.117605_b0300","doi-asserted-by":"crossref","first-page":"16231","DOI":"10.1039\/C9RA10871H","article-title":"Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites","volume":"10","author":"Al-Shakliah","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2024.117605_b0305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2478\/acph-2020-0035","article-title":"Piperazine derivatives as dangerous abused compounds","volume":"70","author":"Koba","year":"2020","journal-title":"Acta Pharmaceut."},{"key":"10.1016\/j.bmc.2024.117605_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136089","article-title":"Green chemistry approach towards Piperazine: anticancer agents","author":"Sharma","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2024.117605_b0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117605_b0320","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/AAC.04654-14","article-title":"Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors","volume":"59","author":"Das","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bmcl.2015.11.009","article-title":"Inhibitors of HIV-1 attachment: the discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore","volume":"26","author":"Swidorski","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0330","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dkt412","article-title":"Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068","volume":"69","author":"Zhou","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0335","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1128\/AAC.00985-13","article-title":"Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes","volume":"57","author":"Lamorte","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejmech.2015.10.027","article-title":"Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers","volume":"106","author":"Rivero-Buceta","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0345","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.02739-13","article-title":"2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors","volume":"58","author":"Tiberi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bmc.2024.117605_b0355","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/v6104095","article-title":"Current perspectives on HIV-1 antiretroviral drug resistance","volume":"6","author":"Iyidogan","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2024.117605_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/v13050843","article-title":"Small molecule HIV-1 attachment inhibitors: discovery, mode of action and structural basis of inhibition","volume":"13","author":"Lai","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2024.117605_b0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10822-019-00258-0","article-title":"Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120","volume":"34","author":"Vangala","year":"2020","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmc.2024.117605_b0370","unstructured":"Yeung KS, Fakas EM, Kadow FJ, Meanwell AN, Taylor M, Johnston D, Coulter S, Wright K. Indole, Azaindole and related heterocyclic N-Substituted piperazine derivatives. US8039486B2 2011."},{"key":"10.1016\/j.bmc.2024.117605_b0375","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bmcl.2012.10.120","article-title":"Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores","volume":"23","author":"Wang","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0380","article-title":"Piperazine-based HIV-1 entry inhibitors: massive in silico library design and screening for gp120 attachment inhibitors","author":"Castillo-Pazos","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.bmc.2024.117605_b0385","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0390","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1021\/jo5016008","article-title":"Synthesis of the 6-azaindole containing HIV-1 attachment inhibitor pro-drug, BMS-663068","volume":"79","author":"Chen","year":"2014","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0395","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00513-13","article-title":"Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors","volume":"57","author":"Li","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0400","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/prot.23005","article-title":"Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry","volume":"79","author":"Da","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.bmc.2024.117605_b0405","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/jm201218m","volume":"55","author":"Kadow","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0410","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1021\/jm301638a","article-title":"Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248","volume":"56","author":"Regueiro-Ren","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0415","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1021\/jm3016377","volume":"56","author":"Regueiro-Ren","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0420","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.bmcl.2019.03.018","article-title":"A survey of core replacements in indole-based HIV-1 attachment inhibitors","volume":"29","author":"Wang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0425","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ejmech.2014.09.012","article-title":"Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806","volume":"86","author":"Liu","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0430","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bmcl.2012.10.118","article-title":"Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores","volume":"23","author":"Bender","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0435","first-page":"25 (6)","article-title":"Composition and orientation of the core region of novel HIV-1 entry inhibitors influences metabolic stability","author":"Karadsheh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117605_b0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jmgm.2013.05.003","article-title":"Is the conformational flexibility of piperazine derivatives important to inhibit HIV-1 replication?","volume":"44","author":"Teixeira","year":"2013","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.bmc.2024.117605_b0445","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1016\/j.bmcl.2009.07.076","article-title":"Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives","volume":"19","author":"Wang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0450","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1021\/jm501772w","article-title":"Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors","volume":"58","author":"Wu","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0455","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/ml1001536","article-title":"Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity","volume":"1","author":"Xue","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0460","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1021\/acsmedchemlett.2c00376","article-title":"Structural and functional characterization of indane-core CD4-mimetic compounds substituted with heterocyclic amines","volume":"14","author":"Chaplain","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0465","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and development of anti-HIV therapeutic agents: progress towards improved HIV medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0470","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1128\/AAC.03630-14","article-title":"Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors","volume":"58","author":"Asin-Milan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0475","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2024.117605_b0480","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0960-894X(01)00381-X","article-title":"Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-Methyl piperazine as a key pharmacophore element","volume":"11","author":"Tagat","year":"2001","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2024.117605_b0485","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14805\/jphchem.2014.art10","article-title":"novo design and in-silico studies of novel bis-arylpiperazine derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"1","author":"Yadav","year":"2014","journal-title":"J Pharm Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0490","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2016.02.051","article-title":"Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: recent advances and future opportunities","volume":"114","author":"Zhang","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0495","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.bmcl.2012.03.019","article-title":"Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine\/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors","volume":"22","author":"Dong","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0500","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bmc.2014.12.052","article-title":"Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists","volume":"23","author":"Hu","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0505","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0960-894X(02)00918-6","article-title":"Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. III: Synthesis, Antiviraland Pharmacokinetic Profiles of Symmetrical Heteroaryl Carboxamides","volume":"13","author":"McCombie","year":"2003","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2024.117605_b0510","doi-asserted-by":"crossref","first-page":"e53636","DOI":"10.1371\/journal.pone.0053636","article-title":"Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117605_b0515","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1016\/j.bmcl.2015.04.036","article-title":"Discovery of novel N-aryl piperazine CXCR4 antagonists","volume":"25","author":"Zhao","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0520","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1016\/j.bmc.2009.07.028","article-title":"Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"17","author":"Zhan","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coviro.2013.03.012","article-title":"HIV-1 reverse transcriptase and antiviral drug resistance. Part 1","volume":"3","author":"Das","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bmc.2024.117605_b0530","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0535","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/cbdd.13766","article-title":"Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants","volume":"97","author":"Smith","year":"2021","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117605_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113450","article-title":"Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0545","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1016\/j.bmc.2013.06.061","article-title":"Synthesis and evaluation of novel 3-(3,5-dimethylbenzyl)uracil analogs as potential anti-HIV-1 agents","volume":"21","author":"Sakakibara","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0550","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjp.2018.10.006","article-title":"Chemical diversity and activity profiles of HIV-1 reverse transcriptase inhibitors from plants","volume":"29","author":"Chinsembu","year":"2019","journal-title":"Rev Bras Farmacogn."},{"key":"10.1016\/j.bmc.2024.117605_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2022.104378","article-title":"Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)","volume":"15","author":"Deng","year":"2022","journal-title":"Arab J Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0560","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2018.09.013","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"158","author":"Gu","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0565","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cbdd.12468","article-title":"Design, synthesis, and biological evaluation of novel 4-aminopiperidinyl-linked 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs","volume":"86","author":"Liu","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117605_b0570","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2013.10.033","article-title":"Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0575","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20132009)","volume":"85","author":"de Bethune","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2024.117605_b0580","doi-asserted-by":"crossref","DOI":"10.1038\/s42004-019-0174-8","article-title":"Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"2","author":"Kang","year":"2019","journal-title":"Commun Chem."},{"key":"10.1016\/j.bmc.2024.117605_b0585","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2016.05.054","article-title":"Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket","volume":"121","author":"Chen","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0590","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.bmc.2014.02.029","article-title":"Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives","volume":"22","author":"Tian","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0595","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1016\/j.bmcl.2013.06.091","article-title":"Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility","volume":"23","author":"Bollini","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0600","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2024.117605_b0605","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1021\/acs.jmedchem.5b01979","article-title":"Development and in vitro evaluation of a microbicide gel formulation for a novel non-nucleoside reverse transcriptase inhibitor belonging to the N-dihydroalkyloxybenzyloxopyrimidines (N-DABOs) family","volume":"59","author":"Tintori","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0610","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/med.20241","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2024.117605_b0615","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3797\/scipharm.1012-17","article-title":"Synthesis and Biological Evaluation of New 3-Phenyl-1-[(4-arylpiperazin-1-yl)alkyl]-piperidine-2,6-diones","volume":"79","author":"Bielenica","year":"2011","journal-title":"Sci Pharm"},{"key":"10.1016\/j.bmc.2024.117605_b0620","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1073\/pnas.94.8.3984","article-title":"Unique features in the structure of the complex between HIV-1reverse transcriptase and the bis(heteroaryl)piperazine (BHAP)U-90152 explain resistance mutations for thisnonnucleoside inhibitor","volume":"94","author":"Esnouf","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117605_b0625","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0969-2126(00)00513-X","article-title":"structural basis for the resilience of Efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase","volume":"8","author":"Ren","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.bmc.2024.117605_b0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.10.029","article-title":"Novel natural non-nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques","volume":"161","author":"Costa","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0635","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/S0103-50532010000100011","article-title":"Synthesis of a novel series of 4-arylpiperazinyl derivatives linked to a 2-(pyridin-3-yl)-1H-benzimidazole as new Delavirdine analogues","volume":"21","author":"Pessoa-Mahana","year":"2010","journal-title":"J Braz Chem Soc"},{"key":"10.1016\/j.bmc.2024.117605_b0640","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/00397910701215759","article-title":"Synthesis of 2-benzothienyl carbonyl 4-arylpiperazines as novel delavirdine analogs","volume":"37","author":"Pessoa-Mahana","year":"2007","journal-title":"Synth Commun"},{"key":"10.1016\/j.bmc.2024.117605_b0645","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1016\/j.bmcl.2018.10.010","article-title":"Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine","volume":"28","author":"Jin","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0650","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0655","doi-asserted-by":"crossref","unstructured":"Navid Soltani Rad M, Behrouz S, Zokaei K, Behrouz M, Ghanbariasad A, Zarenezhad E. Synthesis of some novel 8-(4-Alkylpiperazinyl) caffeine derivatives as potent anti-Leishmania agents. Bioorg Chem. 2022;128:106062. DOI: 10.1016\/j.bioorg.2022.106062.","DOI":"10.1016\/j.bioorg.2022.106062"},{"key":"10.1016\/j.bmc.2024.117605_b0660","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700022","article-title":"Oxazolo[4,5-b]pyridine-based piperazinamides as GSK-3beta Inhibitors with potential for attenuating inflammation and suppression of pro-inflammatory mediators","volume":"350","author":"Tantray","year":"2017","journal-title":"Arch Pharm Chem Life Sci"},{"key":"10.1016\/j.bmc.2024.117605_b0665","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bmcl.2015.01.058","article-title":"Design, synthesis of new beta-carboline derivatives and their selective anti-HIV-2 activity","volume":"25","author":"Ashok","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0670","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1016\/j.bmcl.2012.09.066","article-title":"Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents","volume":"22","author":"Venkatraj","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0675","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3851\/IMP1607","article-title":"Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors","volume":"20","author":"La Regina","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115114","article-title":"Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities","volume":"248","author":"Ming","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0685","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bmcl.2016.11.030","article-title":"Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives","volume":"27","author":"Chander","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0690","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bmcl.2014.12.062","article-title":"Dithiocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies","volume":"25","author":"Bala","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0695","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/15257770.2014.880475","article-title":"Synthesis of potential pyrimidine derivatives via Suzuki cross-coupling reaction as HIV and kinesin Eg5 inhibitors","volume":"33","author":"Al-Masoudi","year":"2014","journal-title":"Nucleos Nucleot Nucl."},{"key":"10.1016\/j.bmc.2024.117605_b0700","doi-asserted-by":"crossref","unstructured":"Huang B, Chen W, Zhao T, et al. Exploiting the Tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J Med Chem. 2019;62 (4):2083-2098. DOI: 10.1021\/acs.jmedchem.8b01729.","DOI":"10.1021\/acs.jmedchem.8b01729"},{"key":"10.1016\/j.bmc.2024.117605_b0705","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s42004-023-00888-4","article-title":"Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"6","author":"Jiang","year":"2023","journal-title":"Commun Chem."},{"key":"10.1016\/j.bmc.2024.117605_b0710","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/14756366.2012.755622","article-title":"Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline-triazine derivatives","volume":"29","author":"Modh","year":"2014","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0715","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144240","article-title":"Synthesis and cytotoxic activity study of novel 2-(aryldiazenyl)-3-methyl-1H-benzo[g]indole derivatives","volume":"26","author":"Arafeh","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117605_b0720","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/cbdd.12456","article-title":"Design, synthesis, and biological evaluation of 1-(thiophen-2-yl)-9H-pyrido[3,4-b]indole derivatives as anti-HIV-1 agents","volume":"85","author":"Ashok","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117605_b0725","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/cbdd.12471","article-title":"Design, synthesis, and anti-HIV evaluation of novel triazine derivatives targeting the entrance channel of the NNRTI binding pocket","volume":"86","author":"Chen","year":"2015","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2024.117605_b0730","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.bmcl.2013.02.021","article-title":"Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors","volume":"23","author":"James","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0735","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.bmc.2016.07.039","article-title":"Computer-aided discovery of anti-HIV agents","volume":"24","author":"Jorgensen","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0740","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40265-013-0015-5","article-title":"Next-generation integrase inhibitors : where to after raltegravir?","volume":"73","author":"Karmon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117605_b0745","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coviro.2014.07.006","article-title":"Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences","volume":"8","author":"Grobler","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bmc.2024.117605_b0750","doi-asserted-by":"crossref","first-page":"e1002584","DOI":"10.1371\/journal.pbio.1002584","article-title":"Structural basis for inhibitor-induced aggregation of HIV integrase","volume":"14","author":"Gupta","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmc.2024.117605_b0755","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00044-016-1631-x","article-title":"Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities","volume":"25","author":"Hajimahdi","year":"2016","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmc.2024.117605_b0760","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm301632e","article-title":"Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor\/p75 (IN-LEDGF\/p75) interaction","volume":"56","author":"Serrao","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.bmc.2024.117605_b0770","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","article-title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","volume":"46","author":"Han","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.bmc.2024.117605_b0775","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0780","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"Penafiel","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0785","doi-asserted-by":"crossref","first-page":"21189","DOI":"10.1074\/jbc.M112.347534","article-title":"New class of HIV-1 integrase (IN) inhibitors with a dual mode of action","volume":"287","author":"Tsiang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119314","article-title":"Recent developments in the synthesis of HIV-1 integrase strand transfer inhibitors incorporating pyridine moiety","volume":"24","author":"Starosotnikov","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117605_b0795","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3851\/IMP2690","article-title":"Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors","volume":"23","author":"Esposito","year":"2014","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bmc.2024.117605_b0800","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1016\/j.bmcl.2010.07.087","article-title":"Synthesis of polyhydroxylated aromatics having amidation of piperazine nitrogen as HIV-1 integrase inhibitor","volume":"20","author":"Yang","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0805","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/jm5001503","article-title":"Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase","volume":"57","author":"Costi","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0810","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bmc.2014.12.059","article-title":"Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors","volume":"23","author":"Wang","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114760","article-title":"Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors","volume":"243","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0820","doi-asserted-by":"crossref","first-page":"e0235483","DOI":"10.1371\/journal.pone.0235483","article-title":"Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study","volume":"15","author":"Zhou","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117605_b0825","first-page":"434","article-title":"Renal effects of novel antiretroviral drugs","volume":"32","author":"Milburn","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bmc.2024.117605_b0830","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1021\/acs.jmedchem.1c02217","article-title":"Pocket-to-lead: structure-based de novo design of novel non-peptidic HIV-1 protease inhibitors using the ligand binding pocket as a template","volume":"65","author":"Kojima","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0835","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acsmedchemlett.2c00310","article-title":"Highly potent and oral macrocyclic peptides as a HIV-1 protease inhibitor: mRNA display-derived hit-to-lead optimization","volume":"13","author":"Kusumoto","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0840","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/acsmedchemlett.7b00386","article-title":"Design and synthesis of piperazine sulfonamide cores leading to highly potent HIV-1 protease inhibitors","volume":"8","author":"Bungard","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117605_b0845","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11904-020-00486-2","article-title":"Novel antiretroviral agents","volume":"17","author":"Cambou","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.bmc.2024.117605_b0850","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/bcp.14759","article-title":"Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults","volume":"87","author":"Pene Dumitrescu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2024.117605_b0855","first-page":"24 (2)","article-title":"Anti-HIV potential of beesioside I derivatives as maturation inhibitors: synthesis, 3D-QSAR, molecular docking and molecular dynamics simulations","author":"Zhao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117605_b0860","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.1021\/jm301040s","article-title":"Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors","volume":"55","author":"Qian","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0865","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1021\/acs.jmedchem.6b00461","article-title":"Incorporation of privileged structures into bevirimat can improve activity against wild-type and bevirimat-resistant HIV-1","volume":"59","author":"Zhao","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117605_b0870","unstructured":"Shetty BV. Antiviral and Antimicrobial Compounds US20140073631A1, 2014."},{"key":"10.1016\/j.bmc.2024.117605_b0875","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/cbdd.12047","article-title":"Synthesis and anti-HIV properties of new carbamate prodrugs of AZT","volume":"80","author":"Solyev","year":"2012","journal-title":"Chem Biol Drug Des"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:25:42Z","timestamp":1760837142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":175,"alternative-id":["S0968089624000191"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117605","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry perspectives on the development of piperazine-containing HIV-1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117605"}}